**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 63362

**Manuscript Type:** MINIREVIEWS

**Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility**

Ji XK *et al*. Role of cyclooxygenase-2 in gastric cancer

Xuan-Ke Ji, Sailaja Vatsalya Madhurapantula, Gui He, Kun-Yan Wang, Chun-Hua Song, Jian-Ying Zhang, Kai-Juan Wang

**Xuan-Ke Ji, Sailaja Vatsalya Madhurapantula, Gui He, Kun-Yan Wang, Chun-Hua Song, Jian-Ying Zhang, Kai-Juan Wang,** College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China

**Xuan-Ke Ji, Sailaja Vatsalya Madhurapantula, Gui He, Kun-Yan Wang, Chun-Hua Song, Jian-Ying Zhang, Kai-Juan Wang,** Department of Epidemiology, College of Public Health, Zhengzhou University, Zhengzhou 450001, Henan Province, China

**Xuan-Ke Ji, Sailaja Vatsalya Madhurapantula, Gui He, Kun-Yan Wang, Chun-Hua Song, Jian-Ying Zhang, Kai-Juan Wang,** Key Laboratory of Tumor Epidemiology of Henan Province, Zhengzhou University, Zhengzhou 450001, Henan Province, China

**Xuan-Ke Ji, Sailaja Vatsalya Madhurapantula, Gui He, Kun-Yan Wang, Chun-Hua Song, Jian-Ying Zhang, Kai-Juan Wang,** State Key Laboratory of Esophageal Cancer Prevention and Treatment, Zhengzhou University, Zhengzhou 450001, Henan Province, China

**Author contributions:** Ji XK, He G, Wang KY, Song CH, Zhang JY, and Wang KJ contributed to conception or design of the study; Ji XK, He G, and Wang KY contributed to acquisition of the data; Ji XK, He G, Wang KY, and Wang KJ contributed to analysis or interpretation of the data; Ji XK contributed to drafting of the manuscript; Madhurapantula SV and Wang KJ contributed to critical revision of the manuscript for important intellectual content.

**Supported by** National Natural Science Foundation of China, No. 81373097.

**Corresponding author: Kai-Juan Wang, PhD, Professor,** College of Public Health, Zhengzhou University, No. 100 Kexue Avenue, Zhengzhou 450001, Henan Province, China. kjwang@163.com

**Received:** January 27, 2021

**Revised:** March 17, 2021

**Accepted:** July 2, 2021

**Published online:** July 27, 2021

**Abstract**

Gastric cancer accounts for the majority cancer-related deaths worldwide. Although various methods have considerably improved the screening, diagnosis, and treatment of gastric cancer, its incidence is still high in Asia, and the 5-year survival rate of advanced gastric cancer patients is only 10%-20%. Therefore, more effective drugs and better screening strategies are needed for reducing the incidence and mortality of gastric cancer. Cyclooxygenase-2 (COX-2) is considered to be the key inducible enzyme in prostaglandins (PGs) synthesis, which is involved in multiple pathways in the inflammatory response. For example, inflammatory cytokines stimulate innate immune responses *via* Toll-like receptors and nuclear factor-kappa B to induce COX-2/PGE2 pathway. In these processes, the production of an inflammatory microenvironment promotes the occurrence of gastric cancer. Epidemiological studies have also indicated that non-steroidal anti-inflammatory drugs can reduce the risk of malignant tumors of the digestive system by blocking the effect of COX-2. However, clinical use of COX-2 inhibitors to prevent or treat gastric cancer may be limited because of potential side effects, especially in the cardiovascular system. Given these side effects and low treatment efficacy, new therapeutic approaches and early screening strategies are urgently needed. Some studies have shown that genetic variation in *COX-2* also play an important role in carcinogenesis. However, the genetic variation analysis in these studies is incomplete and isolated, pointing out only a few single nucleotide polymorphisms (SNPs) and the risk of gastric cancer, and no comprehensive study covering the whole gene region has been carried out. In addition, copy number variation (CNV) is not mentioned. In this review, we summarize the SNPs in the whole *COX-2* gene sequence, including exons, introns, and both the 5’ and 3’ untranslated regions. Results suggest that *COX-2* does not increase its expression through the CNV and the SNPs in *COX-2* may serve as the potential marker to establish risk stratification in the general population. This review synthesizes emerging insights of COX-2 as a biomarker in multiple studies, summarizes the association between whole *COX-2* sequence variation and susceptibility to gastric cancer, and discusses the future prospect of therapeutic intervention, which will be helpful for early screening and further research to find new approaches to gastric cancer treatment.

**Key Words:** Cyclooxygenase-2; Inflammation; Genetic variant; Gastric cancer; Prostaglandin E2

**©The** **Author(s) 2021.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Ji XK, Madhurapantula SV, He G, Wang KY, Song CH, Zhang JY, Wang KJ. Genetic variant of cyclooxygenase-2 in gastric cancer: More inflammation and susceptibility. *World J Gastroenterol* 2021; 27(28): 4653-4666

**URL:** https://www.wjgnet.com/1007-9327/full/v27/i28/4653.htm

**DOI:** https://dx.doi.org/10.3748/wjg.v27.i28.4653

**Core Tip:** Cyclooxygenase-2 (COX-2) is considered to be the key inducible enzyme in prostaglandins synthesis, and non-steroidal anti-inflammatory drugs can reduce the risk of malignant tumors of the digestive system by blocking the effect of COX-2. However, COX-2 inhibitors to prevent or treat gastric cancer may be limited because of their cardiovascular side effects. This review will be helpful for early screening and further research to find new approaches to gastric cancer treatment by summarizing the association between whole *COX-2* sequence variation and susceptibility to gastric cancer and synthesizing the new progress in understanding the role of COX-2 in gastric carcinogenesis.

**INTRODUCTION**

Gastric cancer is the fifth most commonly diagnosed cancer and the third leading cause of cancer-related deaths worldwide. The incidence of gastric cancer remains high in Eastern Asian despite its global decrease in the last few years[1,2]. Approximately 75% of patients with gastric cancer are diagnosed at advanced stage and the median survival is 7-10 mo[3]. Therefore, individualized prevention and early detection and treatment are of clinical significance in improving the survival time and reducing the mortality of gastric cancer.

Environmental factors including smoking, drinking, and *Helicobacter pylori* (*H. pylori*) infection and genetic alterations such as susceptible genetic variants and epigenetic alterations have been associated with gastric carcinogenesis[4,5]. Cyclooxygenase-2 (COX-2) has been extensively studied in carcinogenesis, and its participation in chronic inflammation and various infections (such as *H. pylori* infection and chronic viral hepatitis) significantly increases the risk of cancer[6,7]. In this review, we will summarize the association between whole *COX-2* sequence variation and susceptibility to gastric cancer. We will also discuss the crucial role of *COX-2* in the occurrence of gastric cancer and its mechanisms.

**Molecular characteristics of COX-2**

COX-2 is known as the key inducible enzyme in prostaglandins (PGs) synthesis, and the *COX-2* gene is located at chromosome 1q25.2-25.3 and composed of 9 introns and 10 exons[8]. The 5’ region of the *COX-2* gene has binding sites for several activated transcriptional factors, such as nuclear factor-kappa B (NF-κB), stimulatory protein 1 (SP1), activator protein-2 (AP-2), and transforming growth factor. In order to explore the expression of *COX-2* in normal tissues, the expression data of *COX-2* were downloaded from the genotypic tissue expression (GTEx) database (https://xenabrowser.net/datapages/) and the distribution of *COX-2* expression in different tissues was visualized by plotting an anatomical map with R-3.5.3 software. Detailed data are shown in Supplementary material 1. Previous studies have shown that *COX-2* has negative expression in normal tissues and organs under physiological conditions, though it is constitutively expressed in the brain and kidney. We also found that *COX-2* gene was rarely expressed in normal tissues (including the stomach), but distributed more in the colon and lungs, both in males and females (Figure 1). However, its expression is increased dramatically in response to certain inflammatory stimuli such as cytokines, oncogenes, and tumor inducers[9]. COX-2 have been shown to play crucial roles in tumorigenesis[10]. The COX-2/PGE2 pathway activates macrophage infiltration and further induces cytokine signaling to activate the transcription factors NF-κB and signal transducer and activator of transcription 3 (Stat3)[11,12], which can change the tumor microenvironment and affect the occurrence of cancer.

**Genetic variants of COX-2 in tumorigenesis**

COX-2 has been implicated in the etiology of cancer and its expression has been confirmed to be increased in gastric cancer. Genetic variants may lead to an increase in expression and change in the function of *COX-2*, which may affect the occurrence of cancer. Studies have suggested that *COX-2* single nucleotide polymorphisms (SNPs) may affect the gastric tumorigenesis. However, these studies only focused on a few or particular region SNPs, and lacked an overall description of the whole sequence variation of *COX-2*. In this review, we summarize the SNPs in the whole *COX-2* gene sequence, including exons, introns, and both the 5’ and 3’ untranslated regions (UTR). In addition, we also analyze the copy number variation (CNV) information of *COX-2* in gastric cancer.

***CNV of COX-2 in gastric cancer***

The SNPs of *COX-2* have been widely studied, but its CNV was rarely mentioned. We downloaded the copy number data of the *COX-2* gene in gastric cancer from The Cancer Genome Atlas (TCGA) database (https://www.cancer.gov/about-nci/organization/ccg/research/structural-genomics/tcga), and then visualized the data with R-3.5.3 software (detailed data in Supplementary material 2). The genes displayed are all genes with CNV, but no CNV of the *COX-2* gene was found.

***Association between COX-2 SNPs and gastric cancer***

The SNPs of *COX-2* may have a functional effect on *COX-2* transcription and cause *COX-2* overexpression to change the response to various inflammatory stimuli. However, only a single locus of SNP can explain the occurrence of cancer very little, which is not enough to fully demonstrate the association between *COX-2* SNPs and gastric cancer. We combined data from the TCGA (https://portal.gdc.cancer.gov/repository; downloaded data in Supplementary material 3) and Ensembl (http://grch37.ensembl.org/Homo\_sapiens/Tools/VcftoPed?db=core) using Haploview 4.2 software to screen SNPs. The criteria for screening SNPs were minor allele frequency ≥ 0.05 and pairwise *r*2 < 0.8. All obtained SNPs are shown in Figure 2. At the same time, we retrieved the SNPs that have been studied. The results showed that 14 SNPs were associated with cancer in the whole sequence of *COX-2*, including 9 SNPs associated with gastric cancer (Table 1). At present, five *COX-2* polymorphisms have been extensively studied, including rs5275 and rs689470T>C that are located in the 3’ UTR, as well as rs689466G>A and rs20417G>C mutations that are located in the promoter region with multiple enhancers and transcriptional regulatory elements. SNPs in the *COX-2* promoter region may change the activity of the promoter and C-reactive protein (CRP), which may be related to acute or chronic inflammation[13]. Although SNPs may have functional effects, there are still a large number of functional features of SNPs that have not been discovered, and their mechanism needs to be further studied. Meanwhile, risk estimates of previous studies have been inconsistent. Therefore, we made a summary and pooled analysis of the extracted data. The results showed that rs689466G>A, rs20417G>C, and rs3218625G>A in the promoter region conferred a higher risk of gastric cancer [A *vs* G: odds ratio (OR) = 1.19, 95% confidence interval (CI): 1.10-1.29; C *vs* G: OR = 1.26, 95%CI: 1.12-1.41; and A *vs* G: OR = 1.62; 95%CI: 1.02-2.56]. Similarly, rs5275T>C and rs689470T>C in the 3’UTR were significantly associated with gastric cancer (C *vs* T: OR = 1.14, 95%CI: 1.01-1.29 and TC *vs* TT: OR = 7.49; 95%CI: 1.21-46.2). As to the rs2066826 G>A polymorphism, a significant association was detected in pancreatic cancer (A *vs* G: OR = 1.60, 95%CI: 1.06-2.40, *P* = 0.026). However, rs5279 T>C in the exon region and rs4648298A>G in the 3′ UTR may reduce the risk of gastric and colorectal cancers (TC *vs* TT: OR = 0.24, 95%CI: 0.08-0.73 and G *vs* A: OR = 0.24; 95%CI: 0.10-0.56).

In our previous study of 296 gastric cancer patients and 319 control family members in the Chinese Han population, an increased risk was observed in individuals with the *COX-2* rs689466AA genotype (OR = 2.03; 95%CI: 1.27-3.22), and the association decreased as the degree of relationship decreased[14]. Recently, we further performed genotyping in 660 gastric cancer cases form the First Affiliated Hospital of Zhengzhou University from 2013 to 2015 and 660 control individuals from a community-based cardiovascular diseases survey in the same time. Our results found that individuals with rs20417 GC genotype were more likely to develop gastric cancer (OR = 1.54, 95%CI: 1.08-2.19). Meanwhile, Zhang *et al*[15] found that rs689466 G>A enhanced the transcriptional activity and thus increased the expression of *COX-2* by creating a c-MYB binding site.

These results suggest that the SNPs of the *COX-2* gene plays an important role in the carcinogenesis of gastric cancer, especially the variation in the promoter region which may have functional consequences. In addition, SNPs in the promoter region could enhance *COX-2* gene transcription, affect the stability of mRNA, regulate the inflammatory response, and consequently lead to individual variation in susceptibility to gastric cancer[16,17]. Our study provides a basis for more thoroughly exploring the exact function of *COX-2* in the occurrence of gastric cancer. Further functional studies will be considered and be elaborated in another study.

**Inflammatory mechanism of COX-2 in gastric cancer**

COX-2 overexpression has been found in a variety of cancers, including gastric cancer[18,19]. A large number of studies have shown that many factors (such as *H． pylori* infection, NF-κB activation, K-ras expression, and the dysregulation of some trans-acting regulatory factors) can lead to overexpression of COX-2 and more inflammation in neoplasia[20-23].

***H. pylori infection and COX-2 expression***

It is generally accepted that *H. pylori* infection is an important risk factor for gastric cancer and *H. pylori* has been classified as a class I carcinogen. *H. pylori* infection may trigger various inflammatory pathways to increase cancer risk. A study has shown that 24 h after *H. pylori* infection of the MKN 28 cell line, the level of *COX-2* mRNA transcription and PGE2 expression increased 5-fold and 3-fold, respectively[24]. However, the exact molecular mechanisms underlying the increased expression of COX-2 in gastric cancer patients with *H. pylori* infection remains unclear.

A study found that *H. pylori* infection stimulates Toll-like receptors (TLRs), to activate innate immunity and the COX-2/PGE2 pathway, which induces "infection-associated inflammation" [such as CXCL1, 2, and 5, CCL3 and 4, interleukin (IL)-11, IL-23, and tumor necrosis factor alpha (TNF-α)], to generate an inflammatory microenvironment and further lead to gastric tumorigenesis[25,26]. Another study using AGS gastric cancer cells showed that *H. pylori* (patient isolate) promotes *COX-2* transcription, which may be due to the activation of mitogen-activated protein kinase (MAPK) pathways (ERK1/2, p38, and JNK) and the activation of cAMP response element (CRE) and AP-1 on the *COX-2* promoter by TLR2/TRL9[27]. Jüttner *et al*[28] found that the binding of upstream stimulatory factor 1/2 (USF1 and 2) to the CRE/Ebox site of the *COX-2* promoter promotes the upregulation of *COX-2* after *H. pylori* infection. Another study demonstrated that *H. pylori* infection may lead to the phosphorylation of p38 MAPK and its downstream activating transcription factor 2 (ATF-2), which affects the expression of COX-2[29]. Some studies have pointed out that the expression of COX-2 is induced by NF-κB, which is recognized and activated by c-Src or TLR2/TLR9 and MAPK kinase kinase 14 (MAP3K = NIK)[30]. In addition, *H. pylori* infection promoted the secretion of gastrin, which extended the half-life of *COX-2* mRNA and increased the expression of COX-2[31]. Semple *et al*[32] reported that gastrin upregulates the expression of COX-2 by CCK-2R-mediated JAK2/Stat3 and subsequent PI3K/Akt activation in gastric cancer cell lines. Meanwhile, *H. pylori* infection may also activate NF-κB, which can induce COX-2 expression[33]. Moreover, another study showed that eradication of *H. pylori* infection significantly reduced COX-2 expression[34].

Noteworthy, COX-2 is overexpressed not only in *H. pylori* positive gastritis and gastric cancer, but also in precancerous lesions such as intestinal metaplasia and atrophic gastritis, suggesting that COX-2 plays a key role in the early gastric carcinogenesis[35,36]. These may be associated with individual genetic susceptibility, especially inflammatory genes, such as *COX-2*, *IL-1b*, and *TNF-α* gene polymorphisms in our previous reports[14,37].

***Inflammatory pathway of COX-2***

COX-2 is regulated by multiple pathways in gastric cancer cell lines. The pathway of COX-2/PGE2 has been shown to play crucial roles in tumorigenesis by triggering the production of an inflammatory microenvironment[10,38,39]. However, the exact tumor-promoting mechanism of PGE2 remains unclear. It has been reported that TLR signaling through the adaptor molecule MyD88 induces the COX-2/PGE2 pathway to promote the occurrence of gastritis and gastric cancer[26]. Meanwhile, the expression of COX-2 was significantly reduced when NF-κB signal was blocked by chondroitin sulfate[40]. Some inflammatory cytokines, such as IL-6, IL-8, and TNF-α, can activate NF-κB to induce overexpression of COX-2[41].

It has also been reported that the expression of K-ras and the activation of matrix metalloproteinase-2 (MMP-2) and MMP-9 are significantly related to the increased expression of COX-2[42]. They may jointly promote the occurrence of gastric cancer, but the mechanism is not clear.

Recent studies suggest that the cooperation of the COX-2 ⁄PGE2 pathways and TLR⁄MyD88 signaling through NF-κB activation is crucial in tumorigenesis[26]. Some genetic studies have shown that the activation of carcinogenic Wnt is related to the occurrence of gastric tumors induced by COX-2[10,38]. In the TCGA database, the Wnt signal and the NF-κ B and COX-2 inflammatory pathways were observed to be activated simultaneously in intestinal gastric cancer[26]. The adenomatous polyposis coli (APC) regulates the expression of COX-2 through a β-catenin-independent mechanism[43]. Inducible nitric oxide synthase (iNOS) can increase the activity of COX-2 to upregulate the production of PGs[44].

These results suggest that COX-2 promotes the occurrence of cancer through induction of various inflammatory pathway signaling and generation of an inflammatory microenvironment (Figure 3).

**Role of COX-2 in cancer preventions and therapeutics**

Epidemiological studies have indicated that the application of COX-2 inhibitors can reduce the inflammatory response and suppresses gastrointestinal cancerization. It may be an effective and crucial target to treat patients with atrophic gastritis and reduce the risk of *H. pylori*-related gastric cancer[22,45]. The use of non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin can reduce the risk of malignant tumors of the digestive system by blocking the effect of COX-2[46].

NSAIDs can reduce the number and size of colorectal carcinomas in patients with familial adenomatous polyposis. Celecoxib, an selective COX-2 inhibitor, and NSAID can also reduce the occurrence of digestive system cancers, such as inhibiting the proliferation of gastric, esophageal, and colorectal cancer cells[47,48]. It is estimated that long-term use of NSAIDs can reduce the incidence of colon cancer by 40%-50%[49]. However, studies have shown that the use of NSAIDs is not an effective chemoprophylaxis for all cancer patients, as aspirin has no effect on the incidence of colorectal adenoma or cancer in patients with Lynch syndrome[50]. Therefore, the combined use of COX-2 inhibitors and the development of new inhibitors have gradually emerged and have better antitumor activity. More detailed results are shown in Table 2. Moreover, clinical use of COX-2 inhibitors to prevent or treat gastric cancer may be limited because of potential side effects, especially in the cardiovascular system, such as elevated blood pressure and myocardial infarction[51,52]. Recently, a systematic review of 329 studies suggested that in addition to COX-2-selective inhibitors, NSAIDs also increase the risk of cardiovascular morbidity[53]. These side effects and low treatment efficacy hinder the application of NSAIDs and COX-2 selective inhibitors as chemopreventive drugs to prevent cancer. At the same time, a study indicated that the combined regulation of the inflammatory microenvironment by inhibiting the COX-2/PGE2 and TLR/MyD88 pathways may be an effective strategy to prevent or treat the development and malignant progression of gastrointestinal cancer, especially those with p53 gain-of-function mutations[54]. Therefore, targeting the COX-2/PGE2 pathway combined with TLR/MyD88 signal pathway may inhibit the inflammatory microenvironment and the stemness of gastric tumor cells, which may be an effective strategy for the prevention and treatment of gastric cancer and needs further clinical evaluation[26]. In addition, as the information of genetic susceptibility and *COX-2* SNPs may have the potential to establish risk stratified markers in the general population, it is helpful for early screening and treatment of precancerous lesions in high-risk population groups to reduce the incidence of gastric cancer and avoid unnecessary treatment.

**CONCLUSION**

It has been established that the expression of COX-2 in gastric cancer cells is induced by various pathways including *H. pylori* infection and COX-2 overexpression results in the generation of an inflammatory microenvironment to promote the occurrence of gastric carcinomas. The polymorphisms including rs689466G>A, rs20417G>C, rs3218625G>A, rs5275T>C, and rs689470T>C in *COX-2* confer individuals a higher susceptibility to gastric cancer. NSAIDs can reduce the risk of digestive system malignant tumors. In addition, the combined regulation of the COX-2/PGE2 and TLR/MyD88 signaling pathways may be an effective strategy to prevent or treat the occurrence and development of gastrointestinal tumors. However, these treatments may increase the incidence of cardiovascular diseases. The above results encourage further functional research to find more accurate individualized prevention strategies and better therapies for gastric cancer.

**ACKNOWLEDGEMENTS**

The authors express their gratitude to Dr. Liu M and Dr. Zhang X for giving excellent advice for modification.

**REFERENCES**

1 **Bray F**, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 2018; **68**: 394-424 [PMID: 30207593 DOI: 10.3322/caac.21492]

2 **Ferlay J**, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. *Eur J Cancer* 2018; **103**: 356-387 [PMID: 30100160 DOI: 10.1016/j.ejca.2018.07.005]

3 **Wagner AD**, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. *J Clin Oncol* 2006; **24**: 2903-2909 [PMID: 16782930 DOI: 10.1200/jco.2005.05.0245]

4 **Duan F**, Song C, Zhang J, Wang P, Ye H, Dai L, Zhang J, Wang K. Evaluation of the Epidemiologic Efficacy of Eradicating Helicobacter pylori on Development of Gastric Cancer. *Epidemiol Rev* 2019; **41**: 97-108 [PMID: 31497856 DOI: 10.1093/epirev/mxz006]

5 **Jin G**, Lv J, Yang M, Wang M, Zhu M, Wang T, Yan C, Yu C, Ding Y, Li G, Ren C, Ni J, Zhang R, Guo Y, Bian Z, Zheng Y, Zhang N, Jiang Y, Chen J, Wang Y, Xu D, Zheng H, Yang L, Chen Y, Walters R, Millwood IY, Dai J, Ma H, Chen K, Chen Z, Hu Z, Wei Q, Shen H, Li L. Genetic risk, incident gastric cancer, and healthy lifestyle: a meta-analysis of genome-wide association studies and prospective cohort study. *Lancet Oncol* 2020; **21**: 1378-1386 [PMID: 33002439 DOI: 10.1016/S1470-2045(20)30460-5]

6 **Clemente M**, Sánchez-Archidona AR, Sardón D, Díez L, Martín-Ruiz A, Caceres S, Sassi F, Dolores Pérez-Alenza M, Illera JC, Dunner S, Peña L. Different role of COX-2 and angiogenesis in canine inflammatory and non-inflammatory mammary cancer. *Vet J* 2013; **197**: 427-432 [PMID: 23489848 DOI: 10.1016/j.tvjl.2013.02.009]

7 **Liu D**, He Q, Liu C. Correlations among Helicobacter pylori infection and the expression of cyclooxygenase-2 and vascular endothelial growth factor in gastric mucosa with intestinal metaplasia or dysplasia. *J Gastroenterol Hepatol* 2010; **25**: 795-799 [PMID: 20492336 DOI: 10.1111/j.1440-1746.2009.06168.x]

8 **Hamy AS**, Tury S, Wang X, Gao J, Pierga JY, Giacchetti S, Brain E, Pistilli B, Marty M, Espié M, Benchimol G, Laas E, Laé M, Asselain B, Aouchiche B, Edelman M, Reyal F. Celecoxib With Neoadjuvant Chemotherapy for Breast Cancer Might Worsen Outcomes Differentially by COX-2 Expression and ER Status: Exploratory Analysis of the REMAGUS02 Trial. *J Clin Oncol* 2019; **37**: 624-635 [PMID: 30702971 DOI: 10.1200/JCO.18.00636]

9 **Zhou TJ**, Zhang SL, He CY, Zhuang QY, Han PY, Jiang SW, Yao H, Huang YJ, Ling WH, Lin YC, Lin ZN. Downregulation of mitochondrial cyclooxygenase-2 inhibits the stemness of nasopharyngeal carcinoma by decreasing the activity of dynamin-related protein 1. *Theranostics* 2017; **7**: 1389-1406 [PMID: 28435473 DOI: 10.7150/thno.17647]

10 **Oshima H**, Matsunaga A, Fujimura T, Tsukamoto T, Taketo MM, Oshima M. Carcinogenesis in mouse stomach by simultaneous activation of the Wnt signaling and prostaglandin E2 pathway. *Gastroenterology* 2006; **131**: 1086-1095 [PMID: 17030179 DOI: 10.1053/j.gastro.2006.07.014]

11 **Grivennikov S**, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M. IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. *Cancer Cell* 2009; **15**: 103-113 [PMID: 19185845 DOI: 10.1016/j.ccr.2009.01.001]

12 **Bollrath J**, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. *Cancer Cell* 2009; **15**: 91-102 [PMID: 19185844 DOI: 10.1016/j.ccr.2009.01.002]

13 **Papafili A**, Hill MR, Brull DJ, McAnulty RJ, Marshall RP, Humphries SE, Laurent GJ. Common promoter variant in cyclooxygenase-2 represses gene expression: evidence of role in acute-phase inflammatory response. *Arterioscler Thromb Vasc Biol* 2002; **22**: 1631-1636 [PMID: 12377741 DOI: 10.1161/01.atv.0000030340.80207.c5]

14 **Li Y**, Dai L, Zhang J, Wang P, Chai Y, Ye H, Zhang J, Wang K. Cyclooxygenase-2 polymorphisms and the risk of gastric cancer in various degrees of relationship in the Chinese Han population. *Oncol Lett* 2012; **3**: 107-112 [PMID: 22740864 DOI: 10.3892/ol.2011.426]

15 **Zhang X**, Miao X, Tan W, Ning B, Liu Z, Hong Y, Song W, Guo Y, Zhang X, Shen Y, Qiang B, Kadlubar FF, Lin D. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. *Gastroenterology* 2005; **129**: 565-576 [PMID: 16083713 DOI: 10.1016/j.gastro.2005.05.003]

16 **Piranda DN**, Abreu RBV, Freitas-Alves DR, de Carvalho MA, Vianna-Jorge R. Modulation of the prostaglandin-endoperoxide synthase 2 gene expression by variant haplotypes: influence of the 3'-untranslated region. *Braz J Med Biol Res* 2017; **51**: e6546 [PMID: 29211250 DOI: 10.1590/1414-431X20176546]

17 **Liu F**, Pan K, Zhang X, Zhang Y, Zhang L, Ma J, Dong C, Shen L, Li J, Deng D, Lin D, You W. Genetic variants in cyclooxygenase-2: Expression and risk of gastric cancer and its precursors in a Chinese population. *Gastroenterology* 2006; **130**: 1975-1984 [PMID: 16762620 DOI: 10.1053/j.gastro.2006.03.021]

18 **Wu WK**, Sung JJ, Yu L, Li ZJ, Chu KM, Cho CH. Constitutive hypophosphorylation of extracellular signal-regulated kinases-1/2 and down-regulation of c-Jun in human gastric adenocarcinoma. *Biochem Biophys Res Commun* 2008; **373**: 330-334 [PMID: 18570890 DOI: 10.1016/j.bbrc.2008.06.025]

19 **Brodie AM**, Lu Q, Long BJ, Fulton A, Chen T, Macpherson N, DeJong PC, Blankenstein MA, Nortier JW, Slee PH, van de Ven J, van Gorp JM, Elbers JR, Schipper ME, Blijham GH, Thijssen JH. Aromatase and COX-2 expression in human breast cancers. *J Steroid Biochem Mol Biol* 2001; **79**: 41-47 [PMID: 11850206 DOI: 10.1016/s0960-0760(01)00131-5]

20 **Dai M**, Hu S, Liu CF, Jiang L, Yu W, Li ZL, Guo W, Tang R, Dong CY, Wu TH, Deng WG. BPTF cooperates with p50 NF-κB to promote COX-2 expression and tumor cell growth in lung cancer. *Am J Transl Res* 2019; **11**: 7398-7409 [PMID: 31934287]

21 **Cheng J**, Fan XM. Role of cyclooxygenase-2 in gastric cancer development and progression. *World J Gastroenterol* 2013; **19**: 7361-7368 [PMID: 24259966 DOI: 10.3748/wjg.v19.i42.7361]

22 **Ren J**, Liu J, Sui X. Correlation of COX-2 and MMP-13 expressions with gastric cancer and their effects on prognosis. *J BUON* 2019; **24**: 187-193 [PMID: 30941969]

23 **Clemente SM**, Martínez-Costa OH, Monsalve M, Samhan-Arias AK. Targeting Lipid Peroxidation for Cancer Treatment. *Molecules* 2020; **25** [PMID: 33167334 DOI: 10.3390/molecules25215144]

24 **Xiao F**, Furuta T, Takashima M, Shirai N, Hanai H. Involvement of cyclooxygenase-2 in hyperplastic gastritis induced by Helicobacter pylori infection in C57BL/6 mice. *Aliment Pharmacol Ther* 2001; **15**: 875-886 [PMID: 11380326 DOI: 10.1046/j.1365-2036.2001.00965.x]

25 **Wang K**, Karin M. Tumor-Elicited Inflammation and Colorectal Cancer. *Adv Cancer Res* 2015; **128**: 173-196 [PMID: 26216633 DOI: 10.1016/bs.acr.2015.04.014]

26 **Echizen K**, Hirose O, Maeda Y, Oshima M. Inflammation in gastric cancer: Interplay of the COX-2/prostaglandin E2 and Toll-like receptor/MyD88 pathways. *Cancer Sci* 2016; **107**: 391-397 [PMID: 27079437 DOI: 10.1111/cas.12901]

27 **Chang YJ**, Wu MS, Lin JT, Sheu BS, Muta T, Inoue H, Chen CC. Induction of cyclooxygenase-2 overexpression in human gastric epithelial cells by Helicobacter pylori involves TLR2/TLR9 and c-Src-dependent nuclear factor-kappaB activation. *Mol Pharmacol* 2004; **66**: 1465-1477 [PMID: 15456896 DOI: 10.1124/mol.104.005199]

28 **Jüttner S**, Cramer T, Wessler S, Walduck A, Gao F, Schmitz F, Wunder C, Weber M, Fischer SM, Schmidt WE, Wiedenmann B, Meyer TF, Naumann M, Höcker M. Helicobacter pylori stimulates host cyclooxygenase-2 gene transcription: critical importance of MEK/ERK-dependent activation of USF1/-2 and CREB transcription factors. *Cell Microbiol* 2003; **5**: 821-834 [PMID: 14531897 DOI: 10.1046/j.1462-5822.2003.00324.x]

29 **Li Q**, Liu N, Shen B, Zhou L, Wang Y, Wang Y, Sun J, Fan Z, Liu RH. Helicobacter pylori enhances cyclooxygenase 2 expression *via* p38MAPK/ATF-2 signaling pathway in MKN45 cells. *Cancer Lett* 2009; **278**: 97-103 [PMID: 19201083 DOI: 10.1016/j.canlet.2008.12.032]

30 **Chang YJ**, Wu MS, Lin JT, Chen CC. Helicobacter pylori-Induced invasion and angiogenesis of gastric cells is mediated by cyclooxygenase-2 induction through TLR2/TLR9 and promoter regulation. *J Immunol* 2005; **175**: 8242-8252 [PMID: 16339564 DOI: 10.4049/jimmunol.175.12.8242]

31 **Subramaniam D**, Ramalingam S, May R, Dieckgraefe BK, Berg DE, Pothoulakis C, Houchen CW, Wang TC, Anant S. Gastrin-mediated interleukin-8 and cyclooxygenase-2 gene expression: differential transcriptional and posttranscriptional mechanisms. *Gastroenterology* 2008; **134**: 1070-1082 [PMID: 18395088 DOI: 10.1053/j.gastro.2008.01.040]

32 **Semple G**, Ryder H, Rooker DP, Batt AR, Kendrick DA, Szelke M, Ohta M, Satoh M, Nishida A, Akuzawa S, Miyata K. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. *J Med Chem* 1997; **40**: 331-341 [PMID: 9022799 DOI: 10.1021/jm960669+]

33 **Konturek PC**, Konturek SJ, Brzozowski T. Helicobacter pylori infection in gastric cancerogenesis. *J Physiol Pharmacol* 2009; **60**: 3-21 [PMID: 19826177]

34 **Konturek PC**, Rembiasz K, Konturek SJ, Stachura J, Bielanski W, Galuschka K, Karcz D, Hahn EG. Gene expression of ornithine decarboxylase, cyclooxygenase-2, and gastrin in atrophic gastric mucosa infected with Helicobacter pylori before and after eradication therapy. *Dig Dis Sci* 2003; **48**: 36-46 [PMID: 12645788 DOI: 10.1023/a:1021774029089]

35 **Shao Y**, Sun K, Xu W, Li XL, Shen H, Sun WH. Helicobacter pylori infection, gastrin and cyclooxygenase-2 in gastric carcinogenesis. *World J Gastroenterol* 2014; **20**: 12860-12873 [PMID: 25278683 DOI: 10.3748/wjg.v20.i36.12860]

36 **Nardone G**, Rocco A, Vaira D, Staibano S, Budillon A, Tatangelo F, Sciulli MG, Perna F, Salvatore G, Di Benedetto M, De Rosa G, Patrignani P. Expression of COX-2, mPGE-synthase1, MDR-1 (P-gp), and Bcl-xL: a molecular pathway of H pylori-related gastric carcinogenesis. *J Pathol* 2004; **202**: 305-312 [PMID: 14991895 DOI: 10.1002/path.1512]

37 **Xu Y**, Cao X, Jiang J, Chen Y, Wang K. TNF-α-308/-238 polymorphisms are associated with gastric cancer: A case-control family study in China. *Clin Res Hepatol Gastroenterol* 2017; **41**: 103-109 [PMID: 27373488 DOI: 10.1016/j.clinre.2016.05.014]

38 **Oshima H**, Oguma K, Du YC, Oshima M. Prostaglandin E2, Wnt, and BMP in gastric tumor mouse models. *Cancer Sci* 2009; **100**: 1779-1785 [PMID: 19622104 DOI: 10.1111/j.1349-7006.2009.01258.x]

39 **Ko CJ**, Lan SW, Lu YC, Cheng TS, Lai PF, Tsai CH, Hsu TW, Lin HY, Shyu HY, Wu SR, Lin HH, Hsiao PW, Chen CH, Huang HP, Lee MS. Inhibition of cyclooxygenase-2-mediated matriptase activation contributes to the suppression of prostate cancer cell motility and metastasis. *Oncogene* 2017; **36**: 4597-4609 [PMID: 28368394 DOI: 10.1038/onc.2017.82]

40 **Xu CX**, Jin H, Chung YS, Shin JY, Lee KH, Beck GR Jr, Palmos GN, Choi BD, Cho MH. Chondroitin sulfate extracted from ascidian tunic inhibits phorbol ester-induced expression of Inflammatory factors VCAM-1 and COX-2 by blocking NF-kappaB activation in mouse skin. *J Agric Food Chem* 2008; **56**: 9667-9675 [PMID: 18800802 DOI: 10.1021/jf801578x]

41 **Oshima H**, Oshima M. The inflammatory network in the gastrointestinal tumor microenvironment: lessons from mouse models. *J Gastroenterol* 2012; **47**: 97-106 [PMID: 22218775 DOI: 10.1007/s00535-011-0523-6]

42 **Dicken BJ**, Graham K, Hamilton SM, Andrews S, Lai R, Listgarten J, Jhangri GS, Saunders LD, Damaraju S, Cass C. Lymphovascular invasion is associated with poor survival in gastric cancer: an application of gene-expression and tissue array techniques. *Ann Surg* 2006; **243**: 64-73 [PMID: 16371738 DOI: 10.1097/01.sla.0000194087.96582.3e]

43 **Wu WK**, Sung JJ, Lee CW, Yu J, Cho CH. Cyclooxygenase-2 in tumorigenesis of gastrointestinal cancers: an update on the molecular mechanisms. *Cancer Lett* 2010; **295**: 7-16 [PMID: 20381235 DOI: 10.1016/j.canlet.2010.03.015]

44 **Kim SF**, Huri DA, Snyder SH. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. *Science* 2005; **310**: 1966-1970 [PMID: 16373578 DOI: 10.1126/science.1119407]

45 **Abnet CC**, Freedman ND, Kamangar F, Leitzmann MF, Hollenbeck AR, Schatzkin A. Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis. *Br J Cancer* 2009; **100**: 551-557 [PMID: 19156150 DOI: 10.1038/sj.bjc.6604880]

46 **Thiel A**, Narko K, Heinonen M, Hemmes A, Tomasetto C, Rio MC, Haglund C, Mäkelä TP, Ristimäki A. Inhibition of cyclooxygenase-2 causes regression of gastric adenomas in trefoil factor 1 deficient mice. *Int J Cancer* 2012; **131**: 1032-1041 [PMID: 22034055 DOI: 10.1002/ijc.27331]

47 **Aziz F**, Yang X, Wang X, Yan Q. Anti-LeY antibody enhances therapeutic efficacy of celecoxib against gastric cancer by downregulation of MAPKs/COX-2 signaling pathway: correlation with clinical study. *J Cancer Res Clin Oncol* 2015; **141**: 1221-1235 [PMID: 25527419 DOI: 10.1007/s00432-014-1892-z]

48 **Thompson PA**, Ashbeck EL, Roe DJ, Fales L, Buckmeier J, Wang F, Bhattacharyya A, Hsu CH, Chow SH, Ahnen DJ, Boland CR, Heigh RI, Fay DE, Hamilton SR, Jacobs ET, Martinez EM, Alberts DS, Lance P. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial. *J Natl Cancer Inst* 2016; **108** [PMID: 27530656 DOI: 10.1093/jnci/djw151]

49 **Peek RM Jr**. Prevention of colorectal cancer through the use of COX-2 selective inhibitors. *Cancer Chemother Pharmacol* 2004; **54 Suppl 1**: S50-S56 [PMID: 15309515 DOI: 10.1007/s00280-004-0887-x]

50 **Burn J**, Bishop DT, Mecklin JP, Macrae F, Möslein G, Olschwang S, Bisgaard ML, Ramesar R, Eccles D, Maher ER, Bertario L, Jarvinen HJ, Lindblom A, Evans DG, Lubinski J, Morrison PJ, Ho JW, Vasen HF, Side L, Thomas HJ, Scott RJ, Dunlop M, Barker G, Elliott F, Jass JR, Fodde R, Lynch HT, Mathers JC; CAPP2 Investigators. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. *N Engl J Med* 2008; **359**: 2567-2578 [PMID: 19073976 DOI: 10.1056/NEJMoa0801297]

51 **Antman EM**. Evaluating the Cardiovascular Safety of Nonsteroidal Anti-Inflammatory Drugs. *Circulation* 2017; **135**: 2062-2072 [PMID: 28533319 DOI: 10.1161/CIRCULATIONAHA.117.027288]

52 **Fanelli A**, Ghisi D, Aprile PL, Lapi F. Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications. *Ther Adv Drug Saf* 2017; **8**: 173-182 [PMID: 28607667 DOI: 10.1177/2042098617690485]

53 **Szeto CC**, Sugano K, Wang JG, Fujimoto K, Whittle S, Modi GK, Chen CH, Park JB, Tam LS, Vareesangthip K, Tsoi KKF, Chan FKL. Non-steroidal anti-inflammatory drug (NSAID) therapy in patients with hypertension, cardiovascular, renal or gastrointestinal comorbidities: joint APAGE/APLAR/APSDE/APSH/APSN/PoA recommendations. *Gut* 2020; **69**: 617-629 [PMID: 31937550 DOI: 10.1136/gutjnl-2019-319300]

54 **Echizen K**, Oshima H, Nakayama M, Oshima M. The inflammatory microenvironment that promotes gastrointestinal cancer development and invasion. *Adv Biol Regul* 2018; **68**: 39-45 [PMID: 29428221 DOI: 10.1016/j.jbior.2018.02.001]

55 **Zhang X**, Zhong R, Zhang Z, Yuan J, Liu L, Wang Y, Kadlubar S, Feng F, Miao X. Interaction of cyclooxygenase-2 promoter polymorphisms with Helicobacter pylori infection and risk of gastric cancer. *Mol Carcinog* 2011; **50**: 876-883 [PMID: 21538574 DOI: 10.1002/mc.20784]

56 **Lopes C**, Pereira C, Farinha M, Medeiros R, Dinis-Ribeiro M. Genetic Variations in Prostaglandin E2 Pathway Identified as Susceptibility Biomarkers for Gastric Cancer in an Intermediate Risk European Country. *Int J Mol Sci* 2021; **22** [PMID: 33440718 DOI: 10.3390/ijms22020648]

57 **Liu Y**, Sun H, Hu M, Zhang Y, Chen S, Tighe S, Zhu Y. The Role of Cyclooxygenase-2 in Colorectal Carcinogenesis. *Clin Colorectal Cancer* 2017; **16**: 165-172 [PMID: 27810226 DOI: 10.1016/j.clcc.2016.09.012]

58 **Shin WG**, Kim HJ, Cho SJ, Kim HS, Kim KH, Jang MK, Lee JH, Kim HY. The COX-2-1195AA Genotype Is Associated with Diffuse-Type Gastric Cancer in Korea. *Gut Liver* 2012; **6**: 321-327 [PMID: 22844559 DOI: 10.5009/gnl.2012.6.3.321]

59 **Guo CC**, Wei N, Liang SH, Wang BL, Sha SM, Wu KC. Population-specific genome-wide mapping of expression quantitative trait loci in the colon of Han Chinese. *J Dig Dis* 2016; **17**: 600-609 [PMID: 27534592 DOI: 10.1111/1751-2980.12399]

60 **Zamudio R**, Pereira L, Rocha CD, Berg DE, Muniz-Queiroz T, Sant Anna HP, Cabrera L, Combe JM, Herrera P, Jahuira MH, Leão FB, Lyon F, Prado WA, Rodrigues MR, Rodrigues-Soares F, Santolalla ML, Zolini C, Silva AM, Gilman RH, Tarazona-Santos E, Kehdy FS. Population, Epidemiological, and Functional Genetics of Gastric Cancer Candidate Genes in Peruvians with Predominant Amerindian Ancestry. *Dig Dis Sci* 2016; **61**: 107-116 [PMID: 26391267 DOI: 10.1007/s10620-015-3859-6]

61 **Luo MX**, Long BB, Li F, Zhang C, Pan MT, Huang YQ, Chen B. Roles of Cyclooxygenase-2 gene -765G > C (rs20417) and -1195G > A (rs689466) polymorphisms in gastric cancer: A systematic review and meta-analysis. *Gene* 2019; **685**: 125-135 [PMID: 30391440 DOI: 10.1016/j.gene.2018.10.077]

62 **Sitarz R**, Leguit RJ, de Leng WW, Polak M, Morsink FM, Bakker O, Maciejewski R, Offerhaus GJ, Milne AN. The COX-2 promoter polymorphism -765 G>C is associated with early-onset, conventional and stump gastric cancers. *Mod Pathol* 2008; **21**: 685-690 [PMID: 18311113 DOI: 10.1038/modpathol.2008.36]

63 **Saxena A**, Prasad KN, Ghoshal UC, Bhagat MR, Krishnani N, Husain N. Polymorphism of -765G > C COX-2 is a risk factor for gastric adenocarcinoma and peptic ulcer disease in addition to H pylori infection: a study from northern India. *World J Gastroenterol* 2008; **14**: 1498-1503 [PMID: 18330937 DOI: 10.3748/wjg.14.1498]

64 **Hou L**, Grillo P, Zhu ZZ, Lissowska J, Yeager M, Zatonski W, Zhu G, Baccarelli A, Chanock SJ, Fraumeni JF Jr, Chow WH. COX1 and COX2 polymorphisms and gastric cancer risk in a Polish population. *Anticancer Res* 2007; **27**: 4243-4247 [PMID: 18214026]

65 **Zhang XM**, Zhong R, Liu L, Wang Y, Yuan JX, Wang P, Sun C, Zhang Z, Song WG, Miao XP. Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population. *PLoS One* 2011; **6**: e21894 [PMID: 21779349 DOI: 10.1371/journal.pone.0021894]

66 **Campanholo VM**, Felipe AV, de Lima JM, Pimenta CA, Ventura RM, Forones NM. -765 g>c polymorphism of the cox-2 gene and gastric cancer risk in Brazilian population. *Arq Gastroenterol* 2014; **51**: 79-83 [PMID: 25003256 DOI: 10.1590/s0004-28032014000200002]

67 **He WT**, Liu T, Tang XF, Li YM. The COX-2 -765 G>C polymorphism is associated with increased risk of gastric carcinogenesis in the Chinese Hui ethnic population. *Asian Pac J Cancer Prev* 2014; **15**: 4067-4070 [PMID: 24935598 DOI: 10.7314/apjcp.2014.15.9.4067]

68 **Di Marco S**, Hel Z, Lachance C, Furneaux H, Radzioch D. Polymorphism in the 3'-untranslated region of TNFalpha mRNA impairs binding of the post-transcriptional regulatory protein HuR to TNFalpha mRNA. *Nucleic Acids Res* 2001; **29**: 863-871 [PMID: 11160917 DOI: 10.1093/nar/29.4.863]

69 **Hussain SK**, Mu LN, Cai L, Chang SC, Park SL, Oh SS, Wang Y, Goldstein BY, Ding BG, Jiang Q, Rao J, You NC, Yu SZ, Papp JC, Zhao JK, Wang H, Zhang ZF. Genetic variation in immune regulation and DNA repair pathways and stomach cancer in China. *Cancer Epidemiol Biomarkers Prev* 2009; **18**: 2304-2309 [PMID: 19661089 DOI: 10.1158/1055-9965.EPI-09-0233]

70 **Özhan G**, Lochan R, Leathart JB, Charnley R, Daly AK. Cyclooxygenase-2 polymorphisms and pancreatic cancer susceptibility. *Pancreas* 2011; **40**: 1289-1294 [PMID: 21705955 DOI: 10.1097/MPA.0b013e31821fcc3b]

71 **Gholami M**, Larijani B, Sharifi F, Hasani-Ranjbar S, Taslimi R, Bastami M, Atlasi R, Amoli MM. MicroRNA-binding site polymorphisms and risk of colorectal cancer: A systematic review and meta-analysis. *Cancer Med* 2019; **8**: 7477-7499 [PMID: 31637880 DOI: 10.1002/cam4.2600]

72 **Mosallaei M**, Simonian M, Ahangari F, Miraghajani M, Mortazavi D, Salehi AR, Khosravi S, Salehi R. Single nucleotide polymorphism rs4648298 in miRNAs hsa-miR21 and hsa-miR590 binding site of *COX* gene is a strong colorectal cancer determinant. *J Gastrointest Oncol* 2018; **9**: 448-457 [PMID: 29998010 DOI: 10.21037/jgo.2017.11.01]

73 **Cox DG**, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V; Bellvitge Colorectal Cancer Study Group. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. *Br J Cancer* 2004; **91**: 339-343 [PMID: 15173859 DOI: 10.1038/sj.bjc.6601906]

74 **Li H**, Ren C, Fan Z, Jin G, Du J, Liu L, Zhu C, Lu F, Ding Y, Deng B, Hu Z, Xu Y, Shen H. A genetic variant in 3'-untranslated region of cyclooxygenases-2 gene is associated with risk of gastric cancer in a Chinese population. *DNA Cell Biol* 2012; **31**: 1252-1257 [PMID: 22385256 DOI: 10.1089/dna.2012.1615]

75 **Furuya TK**, Jacob CE, Tomitão MTP, Camacho LCC, Ramos MFKP, Eluf-Neto J, Alves VAF, Zilberstein B, Cecconello I, Ribeiro U Jr, Chammas R. Association between Polymorphisms in Inflammatory Response-Related Genes and the Susceptibility, Progression and Prognosis of the Diffuse Histological Subtype of Gastric Cancer. *Genes (Basel)* 2018; **9** [PMID: 30551681 DOI: 10.3390/genes9120631]

76 **Hu Z**, Miao X, Ma H, Wang X, Tan W, Wei Q, Lin D, Shen H. A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. *Lung Cancer* 2005; **48**: 11-17 [PMID: 15777967 DOI: 10.1016/j.lungcan.2004.09.004]

77 **Li Q**, Liu L, Liu Y, Zhou H, Yang Z, Yuan K, Min W. Five COX-2 gene polymorphisms and risk of breast cancer: an updated meta-analysis based on 19 case-control studies. *Med Oncol* 2015; **32**: 397 [PMID: 25433948 DOI: 10.1007/s12032-014-0397-6]

78 **Niikura R**, Hayakawa Y, Hirata Y, Konishi M, Suzuki N, Ihara S, Yamada A, Ushiku T, Fujishiro M, Fukayama M, Koike K. Distinct Chemopreventive Effects of Aspirin in Diffuse and Intestinal-Type Gastric Cancer. *Cancer Prev Res (Phila)* 2018; **11**: 279-286 [PMID: 29453233 DOI: 10.1158/1940-6207.CAPR-17-0276]

79 **El-Husseiny WM**, El-Sayed MA, Abdel-Aziz NI, El-Azab AS, Asiri YA, Abdel-Aziz AA. Structural alterations based on naproxen scaffold: Synthesis, evaluation of antitumor activity and COX-2 inhibition, and molecular docking. *Eur J Med Chem* 2018; **158**: 134-143 [PMID: 30216848 DOI: 10.1016/j.ejmech.2018.09.007]

80 **Guo Q**, Li Q, Wang J, Liu M, Wang Y, Chen Z, Ye Y, Guan Q, Zhou Y. A comprehensive evaluation of clinical efficacy and safety of celecoxib in combination with chemotherapy in metastatic or postoperative recurrent gastric cancer patients: A preliminary, three-center, clinical trial study. *Medicine (Baltimore)* 2019; **98**: e16234 [PMID: 31277138 DOI: 10.1097/MD.0000000000016234]

81 **Cao Y**, Qu J, Li C, Yang D, Hou K, Zheng H, Liu Y, Qu X. Celecoxib sensitizes gastric cancer to rapamycin *via* inhibition of the Cbl-b-regulated PI3K/Akt pathway. *Tumour Biol* 2015; **36**: 5607-5615 [PMID: 25701378 DOI: 10.1007/s13277-015-3232-6]

82 **Tołoczko-Iwaniuk N**, Dziemiańczyk-Pakieła D, Nowaszewska BK, Celińska-Janowicz K, Miltyk W. Celecoxib in Cancer Therapy and Prevention - Review. *Curr Drug Targets* 2019; **20**: 302-315 [PMID: 30073924 DOI: 10.2174/1389450119666180803121737]

83 **Roberts RB**, Min L, Washington MK, Olsen SJ, Settle SH, Coffey RJ, Threadgill DW. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. *Proc Natl Acad Sci U S A* 2002; **99**: 1521-1526 [PMID: 11818567 DOI: 10.1073/pnas.032678499]

84 **Abdallah FM**, Helmy MW, Katary MA, Ghoneim AI. Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells. *Naunyn Schmiedebergs Arch Pharmacol* 2018; **391**: 1399-1410 [PMID: 30155693 DOI: 10.1007/s00210-018-1557-6]

85 **Zhong J**, Xiu P, Dong X, Wang F, Wei H, Wang X, Xu Z, Liu F, Li T, Wang Y, Li J. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells *via* ER stress-related apoptosis. *Oncol Rep* 2015; **34**: 2142-2150 [PMID: 26252057 DOI: 10.3892/or.2015.4181]

86 **Ren SZ**, Wang ZC, Zhu D, Zhu XH, Shen FQ, Wu SY, Chen JJ, Xu C, Zhu HL. Design, synthesis and biological evaluation of novel ferrocene-pyrazole derivatives containing nitric oxide donors as COX-2 inhibitors for cancer therapy. *Eur J Med Chem* 2018; **157**: 909-924 [PMID: 30149323 DOI: 10.1016/j.ejmech.2018.08.048]

87 **Farzaneh S**, Zeinalzadeh E, Daraei B, Shahhosseini S, Zarghi A. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity. *Anticancer Agents Med Chem* 2018; **18**: 295-301 [PMID: 28971779 DOI: 10.2174/1871520617666171003145533]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest to disclose.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** January 27, 2021

**First decision:** March 7, 2021

**Article in press:** July 2, 2021

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Shang Y **S-Editor:** Gao CC **L-Editor:** Wang TQ **P-Editor:** Liu JH

**Figure Legends**



**Figure 1 Visualization of cyclooxygenase-2 expression in normal tissues from the genotypic tissue expression database.** The red parts indicate the organs with more cyclooxygenase-2 distribution, while the green parts indicate less distribution. A: Distribution of expression in males; B: Distribution of expression in females.



**Figure 2 General location of cyclooxygenase-2 single nucleotide polymorphisms searched by bioinformatics (based on The Cancer Genome Atlas, NCBI, and UCSC).**

****

**Figure 3 Schematic representation of interactions in regulation of cyclooxygenase-2 to generate an inflammatory microenvironment that has been described in the review.** The active pathway of *Helicobacter pylori* infection is shown on the right. TLR: Toll-like receptor; NF-κB: Nuclear factor κB; PGE2: Prostaglandin E2; EP4: Prostaglandin E receptor subtype 4; C-Src: Cellular src; Akt: Protein kinase B; AP-1: Activator protein 1; MEK1: MAP kinase kinase 1; USF: Upstream stimulatory factor; NIK: Mitogen-activated protein kinase kinase kinase 14; Inos: Inducible nitric oxide synthase; MAPK: Mitogen-activated protein kinase; ATF-2: Activating transcription factor 2; TNF-α: tumor necrosis factor-α; IL: Interleukin; CXCL: Chemokine (CXC motif) ligand; CCL: Chemokine (C-C motif) ligand; COX-2: Cyclooxygenase-2.

**Table 1 Summary of single nucleotide polymorphisms in whole region of cyclooxygenase-2 and their association with risk of cancer**

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| SNP ID (rs number) | Chromosomelocation (GRCh38) | Cancer type | Model | Region | Effect | MAF | OR (95%CI) | *P* value | Ref. |
| rs689465A>G | 1:186681714 | Gastric | G/A | Promoter | Significant interaction with *H. pylori* infection | 0.143 | 0.84 (0.57-1.24) | 0.381 | Zhang *et al*[55] |
| rs689466G>A | 1:186681619 | Gastric | A/G | Promoter | Increases transcriptional activity by creating a c-MYB binding site | 0.176 | 1.19 (1.10-1.29) | 0.002a | Li *et al*[14], Piranda *et al*[16], Zhang *et al*[55], Lopes *et al*[56], Liu *et al*[57], Shin *et al*[58], Guo *et al*[59], Zamudio *et al*[60], and Luo *et al*[61] |
| rs20417G>C | 1:186681189 | Gastric | C/G | Promoter | Reduces promoter activity by creating a binding site for NPM and P-NPM | 0.109 | 1.26 (1.12-1.41) | < 0.001a | Li *et al*[14], Piranda *et al*[16], Liu *et al*[17], Zhang *et al*[55], Shin *et al*[58], Sitarz *et al*[62], Saxena *et al*[63], Hou *et al*[64], Zhang *et al*[65], Campanholo *et al*[66], He *et al*[67], and Di Marco *et al*[68] |
| rs3218625G>A | 1:186674409 | Gastric | A/G | Promoter | Enhances activity of *COX-2* *in vitro* by causing the transition of Gly to Aly  | < 0.001 | 1.62 (1.02-2.56) | 0.039a | Zhang *et al*[55] and Zhang *et al*[65] |
| rs5277G>C | 1:186679065 | Gastric | GC/GG | Exon | - | 0.108 | 0.42 (0.13-1.28) | 0.127 | Hussain *et al*[69] |
| rs5278T>C | 1:186676537 | Gastric | TC/TT | Exon | - | 0.021 | 2.27 (0.53-9.69) | 0.270 | Hussain *et al*[69] |
| rs5279T>C | 1:186675946 | Gastric | TC/TT | Exon | - | 0.015 | 0.24 (0.08-0.73) | 0.012a | Hussain *et al*[69] |
| rs2745557G>A | 1:186680089 | Pancreatic | A/G | Intron | - | 0.164 | 0.94 (0.64-1.39) | 0.764 | Özhan *et al*[70] |
| rs2066826G>A | 1:186676795 | Pancreatic | A/G | Intron | - | 0.188 | 1.60 (1.06-2.40) | 0.026a | Özhan *et al*[70] |
| rs4648262G>T | 1:186679617 | Pancreatic | T/G | Intron | - | < 0.001 | 0.62 (0.22-1.73) | 0.364 | Özhan *et al*[70] |
| rs4648298A>G | 1:186672550 | Colorectal | G/A | 3′-UTR | Creates a longer and possibly more stable species of mRNA | 0.021 | 0.44 (0.25-0.75) | 0.003a | Gholami *et al*[71], Mosallaei *et al*[72], and Cox *et al*[73] |
| rs5275T>C | 1:186673926 | Gastric | C/T | 3′-UTR | Stabilizes mRNA of *COX-2* by potential miRNA-binding sites | 0.351 | 1.14 (1.01-1.29) | 0.030a | Piranda *et al*[16], Li *et al*[74], and Furuya *et al*[75] |
| rs689470T>C | 1:186671926 | Gastric | TC/TT | 3′-UTR | Degradation of the mRNA | 0.039 | 7.49 (1.21-46.20) | 0.030a | Hussain *et al*[69] and Hu *et al*[76] |
| rs2206593A>G | 1:186673297 | Breast | G/A | 3′-UTR | - | 0.060 | 0.92 (0.84-1.91) | 0.088 | Li *et al*[77] |

a*P* < 0.05. SNP: Single nucleotide polymorphism; NPM: Nuceophosmin; P-NPM: Phosphorylated NPM; OR: Odds ratio; CI: Confidence interval; COX-2: Cyclooxygenase-2.

**Table 2 Application of cyclooxygenase-2 inhibitors in cancer**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Drug | Cancer type | Effect(s) | Mechanism | Ref. |
| Celecoxib | Gastric | Inhibits tumor growth | Increases CD206 and activates macrophages | Thiel *et al*[46] |
| Aspirin | Gastric | Induces apoptosis; inhibits proliferation; inhibits angiogenesis | Acetylates the active site of COX-2;inhibits PG synthesis; activates caspase-8/Bid and caspase-3 | Liu *et al*[57], and Niikura *et al*[78] |
| Oxadiazole 10c | Colon | Increases antitumor activity; increases sensitivity | Docked into the COX-2 bind site | El-Husseiny *et al*[79] |
| Celecoxib and platinum | Gastric | Prolong overall survival and progression-free survival | - | Guo *et al*[80]  |
| Celecoxib and rapamycin | Gastric | Increase sensitivity | Inhibit PI3K/AKT pathway | Cao *et al*[81] |
| Celecoxib and FOLFOX4 | Gastric | Inhibit angiogenesis | Down-regulate VEGF level | Tołoczko-Iwaniuk *et al*[82] |
| Celecoxib and erlotinib | Colorectal | Reduce angiogenesis; inhibit formation; inhibit expansion | Inhibit EGFR signaling | Roberts *et al*[83] |
| Celecoxib and Curcumin | Hepatocellular | Inhibit angiogenesis; inhibit proliferation; induce apoptosis | Inhibit Akt/NF-κB/PGE2/ROS pathway; inhibit COX-2/PGE2 pathway | Abdallah *et al*[84] |
| Sorafenib and meloxicam | Hepatocellular | Inhibit tumor cell growth; inhibit proliferation; enhance apoptosis | Activate endoplasmic reticulum stress; enhance the cytotoxicity | Zhong *et al*[85] |
| Ferrocene derivatives | Breast/cervical | Suppress tumor growth; increase antiproliferative activity; induce apoptosis | Increase the levels of cytotoxicity and reactive oxygen species; reduce the level of PGE2 | Ren *et al*[86], and Farzaneh *et al*[87] |

COX-2: Cyclooxygenase-2; PGs: Prostaglandins; PI3K: Phosphatidylinositol 3 kinase; Akt (PKB): Protein kinase B; VEGF: Vascular endothelial growth factor; PGE2: Prostaglandin E2; ROS (MDA): Reactive oxygen species measured as malondialdehyde.



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2021 Baishideng Publishing Group Inc. All rights reserved.**